Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
bortezomib
lenalidomide
maintenance therapy
multiple myeloma
stem cell transplant
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 07 2023
15 07 2023
Historique:
revised:
16
01
2023
received:
11
07
2022
accepted:
02
02
2023
pmc-release:
15
07
2024
medline:
23
6
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
Lenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression-free survival and overall survival. However, patients with high-risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard-risk patients. The authors sought to determine the outcomes of bortezomib-based maintenance compared with lenalidomide maintenance in patients with HRMM undergoing ASCT. In total, the authors identified 503 patients with HRMM who were undergoing ASCT within 12 months of diagnosis from January 2013 to December 2018 after receiving triplet novel-agent induction in the Center for International Blood and Marrow Transplant Research database. HRMM was defined as deletion 17p, t(14;16), t(4;14), t(14;20), or chromosome 1q gain. Three hundred fifty-seven patients (67%) received lenalidomide alone, and 146 (33%) received bortezomib-based maintenance (with bortezomib alone in 58%). Patients in the bortezomib-based maintenance group were more likely to harbor two or more high-risk abnormalities and International Staging System stage III disease (30% vs. 22%; p = .01) compared with the lenalidomide group (24% vs. 15%; p < .01). Patients who were receiving lenalidomide maintenance had superior progression-free survival at 2 years compared with those who were receiving either bortezomib monotherapy or combination therapy (75% vs. 63%; p = .009). Overall survival at 2 years was also superior in the lenalidomide group (93% vs. 84%; p = .001). No superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post-transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Sections du résumé
BACKGROUND
Lenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression-free survival and overall survival. However, patients with high-risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard-risk patients. The authors sought to determine the outcomes of bortezomib-based maintenance compared with lenalidomide maintenance in patients with HRMM undergoing ASCT.
METHODS
In total, the authors identified 503 patients with HRMM who were undergoing ASCT within 12 months of diagnosis from January 2013 to December 2018 after receiving triplet novel-agent induction in the Center for International Blood and Marrow Transplant Research database. HRMM was defined as deletion 17p, t(14;16), t(4;14), t(14;20), or chromosome 1q gain.
RESULTS
Three hundred fifty-seven patients (67%) received lenalidomide alone, and 146 (33%) received bortezomib-based maintenance (with bortezomib alone in 58%). Patients in the bortezomib-based maintenance group were more likely to harbor two or more high-risk abnormalities and International Staging System stage III disease (30% vs. 22%; p = .01) compared with the lenalidomide group (24% vs. 15%; p < .01). Patients who were receiving lenalidomide maintenance had superior progression-free survival at 2 years compared with those who were receiving either bortezomib monotherapy or combination therapy (75% vs. 63%; p = .009). Overall survival at 2 years was also superior in the lenalidomide group (93% vs. 84%; p = .001).
CONCLUSIONS
No superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post-transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Identifiants
pubmed: 37021929
doi: 10.1002/cncr.34778
pmc: PMC10516285
mid: NIHMS1918564
doi:
Substances chimiques
Lenalidomide
F0P408N6V4
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2179-2191Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Informations de copyright
© 2023 American Cancer Society.
Références
Lancet Oncol. 2021 Dec;22(12):1705-1720
pubmed: 34774221
Leukemia. 2018 Feb;32(2):383-390
pubmed: 28761118
Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899
pubmed: 27496215
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
Lancet Oncol. 2020 Oct;21(10):1317-1330
pubmed: 32866432
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Lancet Haematol. 2022 Nov;9(11):e822-e832
pubmed: 36209764
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
Bone Marrow Transplant. 2019 Mar;54(3):353-367
pubmed: 29988062
Haematologica. 2010 Jul;95(7):1150-7
pubmed: 20220069
Oncologist. 2018 Jun;23(6):734-739
pubmed: 29438096
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
JAMA Oncol. 2018 Oct 1;4(10):1389-1397
pubmed: 30098165
Leukemia. 2014 Mar;28(3):690-3
pubmed: 24220275
Transplant Cell Ther. 2022 Feb;28(2):83.e1-83.e9
pubmed: 34781066
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
Blood. 2011 Aug 4;118(5):1231-8
pubmed: 21652683
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Blood Cancer J. 2018 Nov 9;8(11):109
pubmed: 30413684
J Clin Oncol. 2020 Jun 10;38(17):1928-1937
pubmed: 32298201
Lancet. 2021 Aug 21;398(10301):665-674
pubmed: 34388396
Leukemia. 2022 Mar;36(3):885-888
pubmed: 34732857
Lancet Oncol. 2023 Jan;24(1):64-76
pubmed: 36528035
N Engl J Med. 2022 Jul 14;387(2):132-147
pubmed: 35660812
Leukemia. 2018 Jan;32(1):102-110
pubmed: 28584253
J Clin Oncol. 2012 Aug 20;30(24):2946-55
pubmed: 22802322
Lancet Haematol. 2017 Sep;4(9):e431-e442
pubmed: 28826616
Lancet Haematol. 2021 Jan;8(1):e45-e54
pubmed: 33357482
Leukemia. 2006 Nov;20(11):2034-40
pubmed: 17024118
J Clin Oncol. 2022 Sep 1;40(25):2901-2912
pubmed: 34898239